Stockscreener 앱 받기
473.42
1.48%
-7.10
시간 외 거래:
472.00
-1.42
-0.30%
전일 마감가:
$480.52
열려 있는:
$479.13
하루 거래량:
274.19K
Relative Volume:
0.72
시가총액:
$20.38B
수익:
$3.13B
순이익/손실:
$1.27B
주가수익비율:
17.94
EPS:
26.3851
순현금흐름:
$1.12B
1주 성능:
-0.05%
1개월 성능:
+1.14%
6개월 성능:
+54.47%
1년 성능:
+28.87%
1일 변동 폭
$467.52
$480.52
1주일 범위
$467.52
$486.33
52주 변동 폭
$266.98
$519.99
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
473.42 | 20.69B | 3.13B | 1.27B | 1.12B | 26.39 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.66 | 58.95B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.78 | 53.73B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.27 | 49.47B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.22 | 39.98B | 17.41B | 1.43B | 1.00B | 1.2182 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Vanguard Group Inc. Lowers Position in United Therapeutics Corporation $UTHR - MarketBeat
Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock - MarketBeat
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight (2026-02-19) - Seeking Alpha
AnaptysBio (ANAB) to Release Quarterly Earnings on Thursday - Defense World
Cabot Corporation (NYSE:CBT) Given Average Rating of “Hold” by Analysts - Defense World
Vertex Casgevy Rollout Tests Gene Editing Role In Vertex Earnings Story - simplywall.st
Oppenheimer & Co. Inc. Takes $407,000 Position in BridgeBio Pharma, Inc. $BBIO - Defense World
Shell Asset Management Co. Decreases Position in United Therapeutics Corporation $UTHR - Defense World
Market Today: Moderna rebounds; oil and gold jump - GuruFocus
Medicenna Therapeutics Announces Participation in Upcoming Conferences - GlobeNewswire
United Therapeutics (UTHR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
8,211 Shares in United Therapeutics Corporation $UTHR Bought by First National Bank of Omaha - MarketBeat
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
UBS reiterates Buy on United Therapeutics stock ahead of trials By Investing.com - Investing.com Nigeria
UBS reiterates Buy on United Therapeutics stock ahead of trials - Investing.com
MidWestOne Financial Group Inc. Raises Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Envestnet Asset Management Inc. Sells 15,252 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Can United Therapeutics Corporation navigate macro headwindsTrade Risk Summary & High Return Stock Watch Alerts - mfd.ru
Market Fear: Can FingerMotion Inc continue delivering strong returnsJuly 2025 Closing Moves & Expert Curated Trade Ideas - baoquankhu1.vn
Assessing United Therapeutics (UTHR) Valuation As Long Term Returns Contrast With Softer Recent Momentum - Yahoo Finance
LSV Asset Management Sells 177,913 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp. (NASDAQ:UTHR) Passes the "Caviar Cruise" Quality Investing Screen - ChartMill
United Therapeutics sets Feb. 25 date for 2025 earnings webcast - Stock Titan
United Therapeutics (NASDAQ:UTHR) COO Sells $10,679,625.00 in Stock - MarketBeat
United Therapeutics Nears Key Data Milestone With Completed TETON-1 IPF Trial - TipRanks
United Therapeutics Corporation $UTHR Shares Sold by Ashton Thomas Private Wealth LLC - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Cuts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Assessing United Therapeutics (UTHR) Valuation After Positive MiroliverELAP Phase 1 Safety And Survival Data - simplywall.st
Aug Fed Impact: Will United Therapeutics Corporation benefit from government policyJuly 2025 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
United Therapeutics Corporation $UTHR Shares Purchased by AE Wealth Management LLC - MarketBeat
United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
United Therapeutics Corporation (UTHR) Stock Analysis: Exploring A 13% Upside Potential - DirectorsTalk Interviews
Bank of New York Mellon Corp Sells 11,016 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Summit Global Investments Sells 3,327 Shares of United Therapeutics Corporation $UTHR - MarketBeat
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack - Yahoo Finance
A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack - Finviz
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) - Finviz
Mutual of America Capital Management LLC Acquires 4,036 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 13,401 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Strs Ohio Has $4.22 Million Stake in United Therapeutics Corporation $UTHR - MarketBeat
What's Going On With United Therapeutics Stock Monday?United Therapeutics (NASDAQ:UTHR) - Benzinga
United Therapeutics reports positive phase 1 results for bioengineered liver By Investing.com - Investing.com Canada
How Investors May Respond To United Therapeutics (UTHR) Positive Early Data For Bioengineered Liver Support Device - Yahoo Finance
United Therapeutics reports positive phase 1 results for bioengineered liver - Investing.com
Retirement Systems of Alabama Sells 18,709 Shares of United Therapeutics Corporation $UTHR - MarketBeat
World’s first FDA-cleared bioengineered liver trial meets survival goal - Stock Titan
United Therapeutics Reports Early Success For External Liver Support In Acute Failure - Sahm
The Best Pharma Stock I’ve Ever Seen - Nanalyze
United Therapeutics appoints biomedical research leader to board By Investing.com - Investing.com Nigeria
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.38%
0.98%
자본화:
|
볼륨(24시간):